| Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
| Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
| Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria |
|
Clinical and Experimental Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress |
|
Expert Review of Anticancer Therapies |
Myelodysplastic Syndromes (MDS) |
| Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes |
|
European Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| Considerations for Drug Development in Myelodysplastic Syndromes |
|
Clinical Cancer Research |
Myelodysplastic Syndromes (MDS) |
| Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review |
|
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
| Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia |
|
Annals of Hematology |
Aplastic Anemia |
